# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo reiterates IGC Pharma (AMEX:IGC) with a Buy and maintains $3.25 price target.
-- Study Deepens Understanding of Treatments for Alzheimer's Patients, Enabling More Effective Treatments --
https://subscriber.politicopro.com/article/2024/05/justice-department-poised-to-post-plans-for-marijuana-reclassification-00158...
https://www.marijuanamoment.net/dea-appears-to-question-marijuanas-medical-value-despite-rescheduling-recommendation/
https://twitter.com/KevinSabet/status/1787569052782846142